- Home
- VSTM
VSTM
Verastem Inc.
as 06-30-2025 12:33pm EST
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NEEDHAM |
| Market Cap: | 425.9M | IPO Year: | 2012 |
| Target Price: | $12.63 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.10 - $9.10 | Next Earning Date: | 08-07-2025 |
| Revenue: | $10,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 129.06% | Revenue Growth (next year): | 306.32% |
Stock Insider Trading Activity of Verastem Inc. (VSTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Calkins Daniel | VSTM | Chief Financial Officer | Jun 20 '25 | Sell | $4.92 | 4,135 | $21,202.05 | 109,945 | |
| Gagnon Robert E. | VSTM | Director | Jun 16 '25 | Sell | $5.65 | 284 | $1,604.60 | 42,242 | |
| Stuglik Brian M | VSTM | Director | Jun 16 '25 | Sell | $5.65 | 594 | $3,356.10 | 102,326 | |
| Paterson Dan | VSTM | President and CEO | Jun 16 '25 | Sell | $5.65 | 335 | $1,892.75 | 461,647 | |
| Calkins Daniel | VSTM | Chief Financial Officer | May 16 '25 | Sell | $8.13 | 11,143 | $90,592.59 | 109,945 | |
| Paterson Dan | VSTM | President and CEO | May 16 '25 | Sell | $8.13 | 58,677 | $477,044.01 | 461,647 | |
| Paterson Dan | VSTM | President and CEO | May 5 '25 | Sell | $7.30 | 820 | $5,986.00 | 461,647 |
Latest Verastem Inc. News
VSTM Breaking Stock News: Dive into VSTM Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
RBC Cuts Price Target on Verastem to $12 From $16, Keeps Outperform, Speculative Risk
MT Newswires
6 days ago
Verastem Doses First Patient in US Study of Oral Cancer Drug VS-7375
Business Wire
6 days ago
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
Zacks
10 days ago
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Business Wire
a month ago
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
Zacks
a month ago
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Business Wire
a month ago
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Simply Wall St.
a month ago
US High Growth Tech Stocks to Watch in May 2025
Compare VSTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VSTM Verastem Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.